FIELD: chemistry.
SUBSTANCE: invention provides to a high degree a safe pharmaceutical drug which is effective for diseases caused by MMP-2 and/or MMP-9. The pharmaceutical drug contains, as an active ingredient, at least one member selected from a group which consists of thiazole derivatives of formula 
(1): where R1 is a phenyl group which can have 1-3 lower alkoxy groups as substitutes in the phenyl ring, and R2 is a pyridyl group which can have 1-3 carboxyl groups as substitutes in the pyridine ring, or salts thereof.
EFFECT: high activity and use when treating diseases such as fibrosis and pulmonary emphysema.
4 cl, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | 2007 |
|
RU2463301C2 |
| MMP-9 REGULATORS AND USE THEREOF | 2008 |
|
RU2474433C2 |
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2820540C2 |
| 2-PYRAZINONE DERIVATIVES FOR TREATING DISEASES OR CONDITIONS WHERE INHIBITING NEUTROPHIL ELASTASE ACTIVITY IS USEFUL | 2007 |
|
RU2448098C2 |
| COMPOSITION FOR RECOVERY OF NORMAL TISSUE FROM FIBROUS TISSUE | 2011 |
|
RU2650796C2 |
| THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | 2015 |
|
RU2678968C2 |
| ARYLSULPHONAMIDE-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | 2005 |
|
RU2406721C2 |
| DIARYLCARBAMIDE FOR TREATING PULMONARY HYPERTENSION | 2006 |
|
RU2431484C2 |
| THERAPEUTIC AGENT APPLICABLE IN PULMONARY FIBROSIS | 2009 |
|
RU2547571C2 |
| PYRIMIDINE DERIVATIVES AND USING THEM IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2581839C2 |
